intended for treatment of research hub

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

This study is testing if a new version of the diabetes and heart failure medicine, Dapagliflozin, works the same as the existing one. Healthy adults take both medicines to see if they're absorbed in the body in the same way.